Plain-English translation of NCT03565341 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This completed trial examined the PiQo4 Picosecond Laser System, a specialized laser device designed to treat melasma—stubborn dark patches that often appear on the face and don't respond well to creams. Researchers tested whether using two different laser wavelengths together worked better than using just one wavelength alone. Participants received up to three laser treatments over three months, with follow-up visits to measure how well their melasma improved.
Melasma is difficult to treat and many people don't see results with standard lightening creams. This trial aimed to find out if combining two different laser wavelengths could offer a more effective way to fade these stubborn dark patches.
Participants received laser treatments on one half of their face at monthly intervals for three months (one wavelength alone on one side, and a combination of two wavelengths on the other side). Each session involved numbing the skin and exposing it to the laser light. Participants then attended follow-up visits at 1, 3, and 6 months after their last treatment so researchers could photograph and evaluate how well the melasma faded. Throughout the entire study and follow-up period, participants agreed to use the same skin care products, apply SPF 50+ sunscreen daily, and avoid other skin treatments or procedures.
AI-generated summary from trial data · Aug 29, 2026 · Not medical advice
United States
Sponsor
Focus Medical, LLC
Enrollment target
~20 participants
Started
July 2018
Primary completion
August 2019
Age range
18 Years – 75 Years
Sex
Female only
Last updated on clinicaltrials.gov in December 2019.